Drug Pipeline

H1 receptor antagonist Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Phase 3
1
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT06305754
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy…		 overall status: "Recruiting" → "Active Not Recruiting"
Active Studies by Phase
Phase 3
2
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870)… Ovarian Cancer Recruiting
NCT06305754 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy… Non-small Cell Lung Cancer (NSCLC) Active, Not Recruiting
Phase 2
NCT06788912 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung… Lung Neoplasm Malignant Recruiting
Sponsors Running H1 receptor antagonist Trials
Merck Sharp & Dohme LLC (3)
Disease Areas
Lung Cancer (2) Non-Small Cell Lung Cancer (NSCLC) (1) Ovarian Cancer (1)
Get alerts when H1 receptor antagonist trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free